Polypharmacy

Subscribe to Selected New Research on Polypharmacy

587 relevant articles (24 outcomes, 36 trials/studies) found for this Therapy

Description: The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)

Relationship Network

Therapy Context: Research Results

Therapeutics: 6127

Drug Therapy: 124082

Polypharmacy: 587

Experts

1.	Uchida, Hiroyuki: 4 articles (08/2008 - 11/2003)
2.	Watanabe, Koichiro: 4 articles (08/2008 - 11/2003)
3.	Yagi, Gohei: 4 articles (08/2008 - 11/2003)
4.	Suzuki, Takefumi: 4 articles (08/2008 - 11/2003)
5.	Kashima, Haruo: 4 articles (08/2008 - 11/2003)
6.	Nomura, Kensuke: 3 articles (08/2008 - 11/2003)
7.	Tanabe, Akira: 3 articles (08/2008 - 11/2003)
8.	Kane, John M: 2 articles (01/2008 - 01/2007)
9.	Zhu, Baojin: 2 articles (01/2008 - 01/2005)
10.	Correll, Christoph U: 2 articles (01/2008 - 01/2007)

Related Diseases

1.	Heart Failure 04/10/2008 - "We need clinical trial data that show definite improvement in outcomes as well as a clear-cut, favourable benefit-risk analysis involving beta-blockers in typical older heart failure patients irrespective of comorbidity and polypharmacy. " 09/01/2002 - "The management of chronic heart failure patients is complicated by the presence of multiple comorbid conditions, polypharmacy, psychosocial concerns and difficulties with adherence to complex medication, dietary regimen, smoking cessation and correct physical activity. " 01/01/2002 - "The management of chronic heart failure in elderly patients is often complicated by the presence of multiple comorbid conditions, polypharmacy, psychosocial and financial concerns, and difficulties with adherence to complex medication and dietary regimens. " 11/01/2001 - "In the management of chronic heart failure, polypharmacy is common, necessary, and often overlooked. " 03/01/2004 - "AIMS: This study evaluates polypharmacy in a relatively unselected community heart failure population following emergency admission and determines the impact of an in-hospital, specialist heart failure care programme on appropriate pharmacotherapy, polypharmacy and drug interactions. " Order ALL the reference details at left...
2.	Seizures (Seizure) 12/01/1993 - "Although it is recognized that the beneficial results of reduced seizure frequency may compensate at least in part for detrimental cognitive AED side effects, polypharmacy and higher AED blood levels can shift this balance. " 01/01/1992 - "The remainder often receive polypharmacy, and current evidence suggests that perhaps only around 10% of these benefit significantly in terms of improved seizure control. " 01/01/1979 - "Reduction in polypharmacy in chronic patients is more difficult, but in many can be achieved with reduction in toxicity, and sometimes improved seizure control. " 03/01/1995 - "The goal of rational polypharmacy is to produce improved seizure control with minimal or no adverse effects." 01/01/1984 - "Reduction in polypharmacy resulted in an improvement in seizure control in 54% of patients. " Order ALL the reference details at left...
3.	Epilepsy (Aura) 06/01/1983 - "Reduction of polypharmacy may be beneficial for patients with intractable epilepsy." 09/01/1988 - "A multifaceted study on childhood refractory epilepsy disclosed an insufficient classification of epilepsies and epileptic seizures, and inappropriate polypharmacy as the most important factors preventing appropriate therapy. " 05/01/2009 - "CONCLUSIONS: Treating and managing epilepsy in the elderly may be complicated by confounding factors, including comorbidities and polypharmacy. " 02/03/2009 - "CONCLUSIONS: Polypharmacy with non-antiepileptic drug (AED) medications is common in both men and women, and is not a situation unique to only elderly patients with epilepsy. " 11/01/2006 - "Higher Child Behavior Checklist scores were associated with such specific medical epilepsy-related factors as etiology, age at onset, and polypharmacy. " Order ALL the reference details at left...
4.	Schizophrenia (Dementia Praecox) 03/01/1981 - "The adoption of LANs in the United Kingdom over the past 13 years is in the author's opinion the most important single improvement in the treatment of schizophrenia; but in the absence of any clear indication that LANs can be discontinued after even 4 years, the emphasis must remain on their proper use: personalised prescriptions (dose reduced with time down to the lowest possible dosage) and caution against unnecessary polypharmacy." 11/01/2008 - "Other areas that may merit future research are efficacy of SGA polypharmacy for schizophrenia accompanied by comorbid conditions (eg, anxiety, suicidal or self-injurious behavior, aggression) and for reducing length of stay in acute care settings." 07/01/2007 - "OBJECTIVE: This study examined trends and costs of second-generation antipsychotic polypharmacy among Medicaid beneficiaries with schizophrenia in San Diego County. " 03/01/2007 - "To date few studies have investigated antipsychotic polypharmacy in Chinese patients with schizophrenia in general and outpatients in particular. " 05/01/2006 - "Definitions of polypharmacy that rely on cross-sectional data or narrow observation periods do not accurately identify patients receiving long-term treatment; in this study, only 10% of patients with schizophrenia received combination treatments for >or=90 days. " Order ALL the reference details at left...
5.	Drug Toxicity (Drug Safety) 09/01/1998 - "Geriatric patients exhibit a decline in the hepatic clearance of certain drugs and a marked increase in the frequency of adverse drug reactions, reflecting an increase in polypharmacy regimens and declines in liver volume and blood flow rather than reduced Phase I metabolism. " 07/01/2004 - "CONCLUSION: While the intervention did not reduce hospitalisation episodes and only led to a modest improvement in quality of life, the development of a mutually acceptable form of face-to-face pharmacist/GP medication review, identification of potentially serious adverse drug reactions, identification of previously unreported complementary medicine use, and enhanced GP awareness of the risks of polypharmacy were positive outcomes of the study." 01/01/2008 - "OBJECTIVE: The aim of the study was to assess the prevalence of polypharmacy and inappropriate drug use in elderly internal-medicine patients in one Austrian center and to define the impact of these and other identified predictors on the occurrence of adverse drug events. " 01/01/2003 - "Most studies were not designed to demonstrate the impact of reducing the number of drugs on the clinical consequences of polypharmacy (nonadherence, adverse drug reactions, drug-drug interactions, increased risk of hospitalisation, and medication errors). " 03/01/2000 - "A study of ambulatory elderly patients with polypharmacy documented that 35% reported experiencing at least one adverse drug event within the previous year. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Carbamazepine (Tegretol)
2.	Xylitol
3.	Sotalol (Sotalol Hydrochloride)
4.	Betaine (C.B.B.)
5.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
6.	carvedilol (Coreg)
7.	olive oil
8.	Antipsychotic Agents (Antipsychotics)
9.	Risperidone (Risperdal Consta)
10.	quetiapine (Seroquel)

Related Therapies and Procedures

1.	Complementary Therapies (Alternative Medicine)
2.	Therapeutics
3.	Length of Stay
4.	Drug Therapy (Chemotherapy)
5.	Medication Errors (Medication Error)

Best Treatments:
Research Summary Report
on Heart Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2790 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>